The global Rapid Tests Market Comprehensive Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments -By Product (Instruments, Consumables, Others), By Technology (Immunoassay, Molecular diagnostics, Others), By Application (Upper respiratory tract infections, Antibiotic-resistant infections, Sepsis), By End-User (Hospitals & clinics, Laboratories, At-home testing, Others)
In 2024, the rapid tests market is experiencing significant growth, driven by the increasing need for quick and accurate diagnostic solutions. Rapid tests, used across various sectors including healthcare, food safety, and environmental testing, offer the advantage of delivering results within minutes to hours. The market has seen substantial advancements in technology, enhancing the sensitivity and specificity of these tests. The COVID-19 pandemic has accelerated the adoption of rapid testing, highlighting the importance of timely diagnostics in managing infectious diseases. The market is also benefiting from the growing demand for at-home testing kits, providing consumers with convenient and accessible diagnostic tools. As healthcare continues to prioritize early detection and preventive care, the rapid tests market is set for robust expansion.
The market report analyses the leading companies in the industry including Abbott Laboratories, Becton, Dickinson and Company, bioMérieux SA, Danaher Corp, DiaSorin S.P.A, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, and Others.
The market trend for rapid tests demonstrates an increasing demand for point-of-care diagnostic solutions among healthcare providers and consumers. Rapid tests offer quick and convenient results, enabling healthcare professionals to make timely decisions for patient care, disease management, and public health interventions. With the ongoing COVID-19 pandemic highlighting the importance of rapid testing for infectious diseases, there is a heightened awareness of the need for accessible and efficient diagnostic tools. This trend is driven by factors such as the growing burden of chronic and infectious diseases, the emphasis on early detection and treatment, and the expansion of healthcare services to underserved populations and remote areas.
The market for rapid tests is primarily driven by advancements in technology and improvements in test accuracy and reliability. Rapid diagnostic technologies, including lateral flow assays, molecular diagnostics, and immunoassays, have undergone significant advancements, leading to faster turnaround times, higher sensitivity and specificity, and enhanced usability. Furthermore, the development of portable and handheld devices, coupled with smartphone integration and connectivity, has facilitated the adoption of rapid tests in various settings, from clinics and hospitals to pharmacies and community health centers. The ability to perform rapid tests with confidence in their accuracy and reliability motivates healthcare providers and consumers to embrace these diagnostic solutions for a wide range of applications, including infectious disease screening, chronic disease management, and monitoring of treatment efficacy.
An opportunity for the rapid tests market lies in diversification into novel test applications and emerging markets. While rapid tests are commonly associated with infectious disease detection, there is potential for expansion into other areas such as cardiac markers, cancer biomarkers, drug screening, and environmental testing. By leveraging the versatility and adaptability of rapid diagnostic technologies, manufacturers can develop innovative tests to address unmet needs in healthcare and non-healthcare sectors. Additionally, there is an opportunity to penetrate emerging markets in regions with growing healthcare infrastructure and increasing demand for diagnostic services, including Asia-Pacific, Latin America, and Africa. By identifying niche applications and expanding into new geographical markets, the rapid tests market can unlock opportunities for growth, innovation, and global impact in the field of point-of-care diagnostics.
Consumables are expected to be the fastest-growing segment in the Rapid Tests Market by product to 2032. The demand for consumables, including test kits, reagents, and swabs, is driven by the increasing adoption of rapid testing across various applications, such as infectious disease diagnostics, drug testing, and pregnancy testing. Consumables are essential for the accurate and efficient performance of rapid tests, ensuring timely results and effective disease management. Additionally, the growing prevalence of infectious diseases and the rising need for point-of-care testing contribute to the segment's rapid growth. The expansion of rapid testing capabilities and the increasing availability of consumables in various healthcare settings support the growth of this segment.
Molecular diagnostics are anticipated to be the fastest-growing segment in the Rapid Tests Market by technology to 2032. The demand for molecular diagnostics is driven by their high accuracy, sensitivity, and ability to detect a wide range of pathogens, including viruses, bacteria, and genetic mutations. Molecular diagnostics are increasingly used in the early detection and management of infectious diseases, oncology, and genetic disorders. Additionally, advancements in molecular testing technologies, such as PCR and next-generation sequencing, contribute to the segment's rapid growth. The expansion of molecular diagnostic applications and the increasing availability of point-of-care molecular tests support the growth of this segment.
Upper respiratory tract infections are expected to be the fastest-growing segment in the Rapid Tests Market by application to 2032. The demand for rapid tests for upper respiratory tract infections is driven by the high prevalence of conditions such as influenza, COVID-19, and the common cold. Rapid tests for these infections provide quick and accurate results, enabling timely diagnosis and treatment. Additionally, the growing awareness of the importance of early detection and the increasing use of rapid tests in clinical and home settings contribute to the segment's rapid growth. The expansion of testing capabilities for respiratory infections and the increasing availability of rapid tests support the growth of this segment.
At-home testing is anticipated to be the fastest-growing segment in the Rapid Tests Market by end-user to 2032. The demand for at-home testing is driven by the increasing consumer preference for convenient and accessible healthcare solutions. At-home testing enables individuals to perform diagnostic tests in the comfort of their own homes, reducing the need for in-person clinic visits. Additionally, the COVID-19 pandemic has accelerated the adoption of at-home testing for infectious diseases and other health conditions. The development of user-friendly, accurate, and reliable at-home test kits further supports the growth of this segment. The expansion of at-home testing capabilities and the increasing availability of test kits in various retail channels support the growth of this segment.
By Product
Instruments
Consumables
Others
By Technology
Immunoassay
Molecular diagnostics
Others
By Application
Upper respiratory tract infections
-Influenza and Parainfluenza virus
-Streptococcus
-Respiratory syncytial virus
Antibiotic resistant infections
Sepsis
-Bacterial Sepsis
-Fungal Sepsis
-Others
By End-User
Hospitals & clinics
Laboratories
At-home testing
Others
Countries Analyzed
North America (US, Canada, Mexico)
Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, South East Asia, Rest of Asia)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Abbott Laboratories
Becton, Dickinson and Company
bioMérieux SA
Danaher Corp
DiaSorin S.P.A
F. Hoffmann-La Roche Ltd
Thermo Fisher Scientific Inc
*- List Not Exhaustive
Chapter 1. TABLE OF CONTENTS
Chapter 2. Introduction to Rapid Tests Market
2.1. Market Overview
2.2. Key Statistics and Report Highlights
2.3. Scope of the Comprehensive Study
2.3.1. Market Definition
2.3.2 Countries and Regions Covered
2.3.3 Research Objective
2.3.4 Units, Currency, and Conversions
2.3.5 Industry Value Chain
2.4. Key Market Segments
2.5. Key Companies
2.6. Study Period
Chapter 3. Strategic Analysis Review
3.1. Rapid Tests Pricing Analysis and Forecast
3.2. Porter’s Five Forces
3.3. Market Ecosystem
3.4. SWOT Analysis
3.5. Regulatory Scenario
3.3. Effects of Inflation, Russia-Ukraine War, moderating economic growth, and other macroeconomic factors
Chapter 4. Competitive Landscape
4.1. Market Share Analysis
4.1.1. Global Rapid Tests Market Share by Company, 2023
4.1.2. Product Offerings of Leading Rapid Tests Companies
4.2. Market Entropy
4.2.1. New Product Launches in the Industry
4.2.2. Mergers, Acquisitions, Joint ventures, and Partnerships
4.3. Key Strategies and Best Practices
Chapter 5. Global Market Projections: Best, Reference, and Low Case Scenarios
5.1. Growth Analysis- Case Scenario Definitions
5.2. Low Growth Case Scenario Forecasts
5.3. Reference Growth Case Scenario Forecasts
5.4. High Growth Case Scenario Forecasts
Chapter 6. Market Dynamics
6.1. Rapid Tests Market Drivers
6.2. Rapid Tests Market Challenges
6.6. Rapid Tests Market Opportunities
6.4. Rapid Tests Market Trends
Chapter 7. Global Rapid Tests Market Outlook Trends
7.1. Global Rapid Tests Revenue (USD Million) and CAGR (%) by Type (2021-2032)
7.2. Global Rapid Tests Revenue (USD Million) and CAGR (%) by Application (2021-2032)
7.3. Global Rapid Tests Revenue (USD Million) and CAGR (%) by Product (2021-2032)
By Product
Instruments
Consumables
Others
By Technology
Immunoassay
Molecular diagnostics
Others
By Application
Upper respiratory tract infections
-Influenza and Parainfluenza virus
-Streptococcus
-Respiratory syncytial virus
Antibiotic resistant infections
Sepsis
-Bacterial Sepsis
-Fungal Sepsis
-Others
By End-User
Hospitals & clinics
Laboratories
At-home testing
Others
Chapter 8. Global Rapid Tests Regional Analysis and Outlook
8.1. Global Rapid Tests Revenue (USD Million) By Regions (2021- 2032)
8.2. North America Rapid Tests Revenue (USD Million) by Country (2021-2032)
8.2.1. United States Rapid Tests Regional Analysis and Outlook
8.2.2. Canada Rapid Tests Regional Analysis and Outlook
8.2.3. Mexico Rapid Tests Regional Analysis and Outlook
8.3. Europe Rapid Tests Revenue (USD Million), by Country (2021-2032)
8.3.1. Germany Rapid Tests Regional Analysis and Outlook
8.3.2. France Rapid Tests Regional Analysis and Outlook
8.3.3. United Kingdom Rapid Tests Regional Analysis and Outlook
8.3.4. Spain Rapid Tests Regional Analysis and Outlook
8.3.5. Italy Rapid Tests Regional Analysis and Outlook
8.3.6. Russia Rapid Tests Regional Analysis and Outlook
8.3.7. Rest of Europe Rapid Tests Regional Analysis and Outlook
8.4. Asia Pacific Rapid Tests Revenue (USD Million) by Country (2021-2032)
8.4.1. China Rapid Tests Regional Analysis and Outlook
8.4.2. Japan Rapid Tests Regional Analysis and Outlook
8.4.3. India Rapid Tests Regional Analysis and Outlook
8.4.4. South Korea Rapid Tests Regional Analysis and Outlook
8.4.5. Australia Rapid Tests Regional Analysis and Outlook
8.4.6. South East Asia Rapid Tests Regional Analysis and Outlook
8.4.7. Rest of Asia Pacific Rapid Tests Regional Analysis and Outlook
8.5. South America Rapid Tests Revenue (USD Million), by Country (2021-2032)
8.5.1. Brazil Rapid Tests Regional Analysis and Outlook
8.5.2. Argentina Rapid Tests Regional Analysis and Outlook
8.5.3. Rest of South America Rapid Tests Regional Analysis and Outlook
8.6. Middle East and Africa Rapid Tests Revenue (USD Million) by Country (2021-2032)
8.6.1. Middle East Rapid Tests Regional Analysis and Outlook
8.6.2. Africa Rapid Tests Regional Analysis and Outlook
Chapter 9. North America Rapid Tests Analysis and Outlook
9.1. North America Rapid Tests Revenue (USD Million) by Segments (2021-2032)
9.1.1. North America Rapid Tests Revenue (USD Million) by Type (2021-2032)
9.1.2. North America Rapid Tests Revenue (USD Million) by Application (2021-2032)
9.1.3. North America Rapid Tests Revenue (USD Million) by Product (2021-2032)
By Product
Instruments
Consumables
Others
By Technology
Immunoassay
Molecular diagnostics
Others
By Application
Upper respiratory tract infections
-Influenza and Parainfluenza virus
-Streptococcus
-Respiratory syncytial virus
Antibiotic resistant infections
Sepsis
-Bacterial Sepsis
-Fungal Sepsis
-Others
By End-User
Hospitals & clinics
Laboratories
At-home testing
Others
Chapter 10. Europe Rapid Tests Analysis and Outlook
10.1. Europe Rapid Tests Revenue (USD Million), by Segments (USD Million) (2021-2032)
10.1.1. Europe Rapid Tests Revenue (USD Million) by Type (2021-2032)
10.1.2. Europe Rapid Tests Revenue (USD Million) by Application (2021-2032)
10.1.3. Europe Rapid Tests Revenue (USD Million) by Product (2021-2032)
By Product
Instruments
Consumables
Others
By Technology
Immunoassay
Molecular diagnostics
Others
By Application
Upper respiratory tract infections
-Influenza and Parainfluenza virus
-Streptococcus
-Respiratory syncytial virus
Antibiotic resistant infections
Sepsis
-Bacterial Sepsis
-Fungal Sepsis
-Others
By End-User
Hospitals & clinics
Laboratories
At-home testing
Others
Chapter 11. Asia Pacific Rapid Tests Analysis and Outlook
11.1. Asia Pacific Rapid Tests Revenue (USD Million), and Revenue (USD Million) by Segments (2021-2032)
11.1.1. Asia Pacific Rapid Tests Revenue (USD Million) by Type (2021-2032)
11.1.2. Asia Pacific Rapid Tests Revenue (USD Million) by Application (2021-2032)
11.1.3. Asia Pacific Rapid Tests Revenue (USD Million) by Product (2021-2032)
By Product
Instruments
Consumables
Others
By Technology
Immunoassay
Molecular diagnostics
Others
By Application
Upper respiratory tract infections
-Influenza and Parainfluenza virus
-Streptococcus
-Respiratory syncytial virus
Antibiotic resistant infections
Sepsis
-Bacterial Sepsis
-Fungal Sepsis
-Others
By End-User
Hospitals & clinics
Laboratories
At-home testing
Others
Chapter 12. South America Rapid Tests Analysis and Outlook
12.1. South America Rapid Tests Revenue (USD Million), by Segments (2021-2032)
12.1.1. South America Rapid Tests Revenue (USD Million) by Type (2021-2032)
12.1.2. South America Rapid Tests Revenue (USD Million) by Application (2021-2032)
12.1.3. South America Rapid Tests Revenue (USD Million) by Product (2021-2032)
By Product
Instruments
Consumables
Others
By Technology
Immunoassay
Molecular diagnostics
Others
By Application
Upper respiratory tract infections
-Influenza and Parainfluenza virus
-Streptococcus
-Respiratory syncytial virus
Antibiotic resistant infections
Sepsis
-Bacterial Sepsis
-Fungal Sepsis
-Others
By End-User
Hospitals & clinics
Laboratories
At-home testing
Others
Chapter 13. Middle East and Africa Rapid Tests Analysis and Outlook
13.1. Middle East and Africa Rapid Tests Revenue (USD Million), by Segments (2021-2032)
13.1.1. Middle East and Africa Rapid Tests Revenue (USD Million) by Type (2021-2032)
13.1.2. Middle East and Africa Rapid Tests Revenue (USD Million) by Application (2021-2032)
13.1.3. Middle East and Africa Rapid Tests Revenue (USD Million) by Product (2021-2032)
By Product
Instruments
Consumables
Others
By Technology
Immunoassay
Molecular diagnostics
Others
By Application
Upper respiratory tract infections
-Influenza and Parainfluenza virus
-Streptococcus
-Respiratory syncytial virus
Antibiotic resistant infections
Sepsis
-Bacterial Sepsis
-Fungal Sepsis
-Others
By End-User
Hospitals & clinics
Laboratories
At-home testing
Others
Chapter 14. Rapid Tests Company Profiles
14.1 Business Overview
14.2 Product Profiles
14.3 SWOT Profiles
14.5 Recent Developments
14.6 Financial Profile
List of Companies
Abbott Laboratories
Becton, Dickinson and Company
bioMérieux SA
Danaher Corp
DiaSorin S.P.A
F. Hoffmann-La Roche Ltd
Thermo Fisher Scientific Inc
15. Methodology and Data Sources
15.1 Customization Offerings
15.2 Subscription Services
15.3 Related Reports
15.4 Publisher Expertise
LIST OF TABLES
Table 1 Market Segmentation Analysis
Table 2 Global Rapid Tests Market Share of Leading Companies, 2023
Table 3 Product Offerings of Leading Companies
Table 4 Low Growth Scenario Forecasts
Table 5 Reference Case Growth Scenario
Table 6 High Growth Case Scenario
Table 7 Global Rapid Tests Revenue (USD Million) And CAGR (%) By Type (2021-2032)
Table 8 Global Rapid Tests Revenue (USD Million) And CAGR (%) By Application (2021-2032)
Table 9 Global Rapid Tests Revenue (USD Million) And CAGR (%) By Product (2021-2032)
Table 10 Global Rapid Tests Market Revenue (USD Million) By Regions (2021-2032)
Table 11 Global Rapid Tests Market Share (%) By Regions (2021-2032)
Table 12 North America Rapid Tests Revenue (USD Million) By Country (2021-2032)
Table 13 Europe Rapid Tests Revenue (USD Million) By Country (2021-2032)
Table 14 Asia Pacific Rapid Tests Revenue (USD Million) By Country (2021-2032)
Table 15 South America Rapid Tests Revenue (USD Million) By Country (2021-2032)
Table 16 Middle East and Africa Rapid Tests Revenue (USD Million) By Region (2021-2032)
Table 17 North America Rapid Tests Revenue (USD Million) By Type (2021-2032)
Table 18 North America Rapid Tests Revenue (USD Million) By Application (2021-2032)
Table 19 North America Rapid Tests Revenue (USD Million) By Product (2021-2032)
Table 20 Europe Rapid Tests Revenue (USD Million) By Type (2021-2032)
Table 21 Europe Rapid Tests Revenue (USD Million) By Application (2021-2032)
Table 22 Europe Rapid Tests Revenue (USD Million) By Product (2021-2032)
Table 23 Asia Pacific Rapid Tests Revenue (USD Million) By Type (2021-2032)
Table 24 Asia Pacific Rapid Tests Revenue (USD Million) By Application (2021-2032)
Table 25 Asia Pacific Rapid Tests Revenue (USD Million) By Product (2021-2032)
Table 26 South America Rapid Tests Revenue (USD Million) By Type (2021-2032)
Table 27 South America Rapid Tests Revenue (USD Million) By Application (2021-2032)
Table 28 South America Rapid Tests Revenue (USD Million) By Product (2021-2032)
Table 29 Middle East and Africa Rapid Tests Revenue (USD Million) By Type (2021-2032)
Table 30 Middle East and Africa Rapid Tests Revenue (USD Million) By Application (2021-2032)
Table 31 Middle East and Africa Rapid Tests Revenue (USD Million) By Product (2021-2032)
LIST OF FIGURES
Figure 1. Market Scope
Figure 2. Pricing Forecasts Per Unit, 2023- 2032
Figure 3. Porter’s Five Forces
Figure 4. Global Rapid Tests Market Revenue (USD Million) By Regions (2021-2032)
Figure 5. Global Rapid Tests Market Share (%) By Regions (2023)
Figure 6. North America Rapid Tests Revenue (USD Million) By Country (2021-2032)
Figure 7. United States Rapid Tests Revenue (USD Million) By Country (2021-2032)
Figure 8. Canada Rapid Tests Revenue (USD Million) By Country (2021-2032)
Figure 9. Mexico Rapid Tests Revenue (USD Million) By Country (2021-2032)
Figure 10. Europe Rapid Tests Revenue (USD Million) By Country (2021-2032)
Figure 11. Germany Rapid Tests Revenue (USD Million) By Country (2021-2032)
Figure 12. France Rapid Tests Revenue (USD Million) By Country (2021-2032)
Figure 13. United Kingdom Rapid Tests Revenue (USD Million) By Country (2021-2032)
Figure 14. Spain Rapid Tests Revenue (USD Million) By Country (2021-2032)
Figure 15. Italy Rapid Tests Revenue (USD Million) By Country (2021-2032)
Figure 16. Russia Rapid Tests Revenue (USD Million) By Country (2021-2032)
Figure 17. Rest of Europe Rapid Tests Revenue (USD Million) By Country (2021-2032)
Figure 11. Asia Pacific Rapid Tests Revenue (USD Million) By Country (2021-2032)
Figure 12. China Rapid Tests Revenue (USD Million) By Country (2021-2032)
Figure 13. Japan Rapid Tests Revenue (USD Million) By Country (2021-2032)
Figure 14. India Rapid Tests Revenue (USD Million) By Country (2021-2032)
Figure 15. South Korea Rapid Tests Revenue (USD Million) By Country (2021-2032)
Figure 16. Australia Rapid Tests Revenue (USD Million) By Country (2021-2032)
Figure 17. South East Asia Rapid Tests Revenue (USD Million) By Country (2021-2032)
Figure 18. South America Rapid Tests Revenue (USD Million) By Country (2021-2032)
Figure 19. Brazil Rapid Tests Revenue (USD Million) By Country (2021-2032)
Figure 20. Argentina Rapid Tests Revenue (USD Million) By Country (2021-2032)
Figure 21. Rest of Asia Pacific Rapid Tests Revenue (USD Million) By Country (2021-2032)
Figure 22. Middle East and Africa Rapid Tests Revenue (USD Million) By Region (2021-2032)
Figure 23. Saudi Arabia Rapid Tests Revenue (USD Million) By Region (2021-2032)
Figure 24. The UAE Rapid Tests Revenue (USD Million) By Region (2021-2032)
Figure 25. Rest of Middle East Rapid Tests Revenue (USD Million) By Region (2021-2032)
Figure 26. South Africa Rapid Tests Revenue (USD Million) By Region (2021-2032)
Figure 27. Africa Rapid Tests Revenue (USD Million) By Region (2021-2032)
Figure 28. North America Rapid Tests Revenue (USD Million) By Type (2021-2032)
Figure 29. North America Rapid Tests Revenue (USD Million) By Application (2021-2032)
Figure 30. North America Rapid Tests Revenue (USD Million) By Product (2021-2032)
Figure 31. Europe Rapid Tests Revenue (USD Million) By Type (2021-2032)
Figure 32. Europe Rapid Tests Revenue (USD Million) By Application (2021-2032)
Figure 33. Europe Rapid Tests Revenue (USD Million) By Product (2021-2032)
Figure 34. Asia Pacific Rapid Tests Revenue (USD Million) By Type (2021-2032)
Figure 35. Asia Pacific Rapid Tests Revenue (USD Million) By Application (2021-2032)
Figure 36. Asia Pacific Rapid Tests Revenue (USD Million) By Product (2021-2032)
Figure 37. South America Rapid Tests Revenue (USD Million) By Type (2021-2032)
Figure 38. South America Rapid Tests Revenue (USD Million) By Application (2021-2032)
Figure 39. South America Rapid Tests Revenue (USD Million) By Product (2021-2032)
Figure 40. Middle East and Africa Rapid Tests Revenue (USD Million) By Type (2021-2032)
Figure 41. Middle East and Africa Rapid Tests Revenue (USD Million) By Application (2021-2032)
Figure 42. Middle East and Africa Rapid Tests Revenue (USD Million) By Product (2021-2032)
By Product
Instruments
Consumables
Others
By Technology
Immunoassay
Molecular diagnostics
Others
By Application
Upper respiratory tract infections
-Influenza and Parainfluenza virus
-Streptococcus
-Respiratory syncytial virus
Antibiotic resistant infections
Sepsis
-Bacterial Sepsis
-Fungal Sepsis
-Others
By End-User
Hospitals & clinics
Laboratories
At-home testing
Others
Countries Analyzed
North America (US, Canada, Mexico)
Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, South East Asia, Rest of Asia)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Global Rapid Tests Market Size is valued at $17.2 Billion in 2024 and is forecast to register a growth rate (CAGR) of 7.1% to reach $29.8 Billion by 2032.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Abbott Laboratories, Becton, Dickinson and Company, bioMérieux SA, Danaher Corp, DiaSorin S.P.A, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2032; Currency: Revenue (USD); Volume